Measurement of Plasma and Intracellular Concentrations of Raltegravir in Patients Infected With Human Immunodeficiency Virus
Status: Completed
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY
The primary purpose of this study is to analyze and compare plasma and intracellular concentrations of Raltegravir (RAL) in blood plasma and in peripheral blood mononuclear cells, using high performance liquid chromatography (HPLC).
Eligibility
Participation Requirements
Sex: All
Minimum Age: 19
Healthy Volunteers: f
View:
• Be of age greater than or equal to 19 years
• Have documented HIV
• Be taking RAL for at least 7 days
Locations
United States
Nebraska
University of Nebraska Medical Center
Omaha
Time Frame
Start Date: 2010-10-01
Completion Date: 2011-06-30
Participants
Target number of participants: 12
Treatments
Experimental: Raltegravir
Authors
Sponsors
Leads: University of Nebraska